Waystar Is Exploring Strategic Options, Including a Sale. The RCM Platform Market Is Entering a New Valuation Test.

Waystar is evaluating strategic options that include a potential sale, Reuters reported Tuesday. The process is early and may not lead to a transaction. But for the revenue cycle market, the more important signal is what a potential buyer would be paying for: not simply healthcare software, but scaled transaction infrastructure sitting between providers, payers and payment workflows.

What Reuters reported

Reuters reported that Waystar has hired Evercore to advise on an early-stage strategic review and that Barclays is also advising the company. Sources cautioned that the plans could change and a sale may not materialize.

Waystar shares rose more than 8% after the report. Reuters calculated the company's market value at approximately $5.2 billion after the move. The company went public in 2024 after years of private-equity ownership and was originally formed through the 2017 merger of ZirMed and Navicure.

EQT remains Waystar's largest shareholder with a 13% stake, followed by the Canada Pension Plan Investment Board at 10%, according to LSEG data cited by Reuters.

Why this matters beyond one company

Waystar sits in a strategically important part of healthcare administration. Its products support payment and revenue-cycle workflows used by hospitals and physician organizations, putting the company inside the operational path between care delivery and reimbursement.

That position matters because the RCM market is separating into two categories. One group consists of point applications that automate individual tasks. The other consists of platforms embedded deeply enough in claims, eligibility, payments and payer-provider transactions that replacing them requires changing core infrastructure.

If a sale process advances, buyers will effectively be assigning a value to that infrastructure advantage.

AI is part of the valuation debate

Reuters noted that Waystar's stock had been under pressure as investors grew concerned that advances in artificial intelligence could disrupt software companies. That concern is particularly relevant in RCM, where coding, denial work, claim edits, patient access and collections are all becoming targets for AI-native automation.

But AI can cut both ways for a company like Waystar.

• AI can compress the value of workflow software. If a task can be automated by an agent, buyers may be less willing to pay premium multiples for applications built around manual workflow orchestration.
• Infrastructure can become more valuable. AI agents still need transaction rails, payer connectivity, claims data, payment data and trusted access to production workflows.
• Distribution matters more. An incumbent platform with deep provider penetration can distribute new automation faster than a standalone startup.
• Data becomes strategic. The more claims and payment activity a platform sees, the more context it can potentially use to improve automation, benchmarking and payer intelligence.

The RCM market could be repriced around infrastructure

For years, healthcare software companies often tried to distinguish themselves from labor-heavy services businesses because public markets typically rewarded software with higher valuation multiples. Reuters notes that Waystar itself emphasized its position as a software company automating administrative work rather than a services organization dependent on people.

AI is now changing that valuation framework. Software that mainly digitizes work may face pressure if AI can perform the work directly. Platforms that own transaction flow, connectivity and embedded distribution may prove more durable.

That distinction should matter to every RCM investor and operator evaluating the next generation of vendors.

What a buyer would actually be buying

A potential acquirer would not simply be buying a collection of RCM modules. The strategic value would come from Waystar's installed footprint, connectivity and position in the healthcare payment flow.

That creates several possible sources of value without assuming who a buyer might be: cross-selling additional automation into an existing provider base, layering AI agents over established transaction workflows, using payment and claims data to build higher-value intelligence products, and consolidating adjacent revenue-cycle infrastructure around a scaled platform.

In other words, the asset is potentially more valuable as a control point than as a feature set.

The private-market question

A return to private ownership would also be notable. Public software markets are forcing healthcare technology companies to defend growth, margins and AI durability every quarter. A private owner can underwrite a longer transformation period, invest aggressively in product changes and potentially use the platform for additional acquisitions.

That does not mean a sale is inevitable. Reuters explicitly reports the process is early and may not result in a deal. But even an auction that does not close could establish an important valuation benchmark for the broader RCM technology market.

The RCAI takeaway

Waystar exploring strategic options is bigger than another healthcare software deal rumor.

It arrives at a moment when AI is forcing investors to decide which parts of healthcare software are vulnerable to automation and which parts become more valuable because automation depends on them.

For revenue cycle, the dividing line may increasingly be infrastructure. Applications can be rebuilt. Work queues can be automated. But platforms embedded in the actual movement of claims, eligibility information, payments and payer-provider transactions occupy a different strategic position.

If Waystar ultimately changes hands, the purchase price will tell the RCM market a great deal about what that position is worth.